$0.57
+0.01 (+1.74%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where CTXR is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional
Held by 4 tracked-famous managers (CITADEL ADVISORS LLC, JANE STREET GROUP, LLC, TWO SIGMA INVESTMENTS, LP, SUSQUEHANNA INTERNATIONAL GROUP, LLP) · FINRA short interest 8.3 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Safety and Efficacy of CITI-002 in Adult Patients With Moderate Grade HemorrhoidsNCT05348200Change in Hemorrhoid symptomsRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Monad 1, Monad 2, Monad 3, Combination - CITI-002 (low dose), Combination - CITI-002 (high dose) | Hemorrhoids | 304 | 2023-04-20actual | 2023-08-31 |
| Safety and Efficacy of Hydrocortisone and Lidocaine Treatment of Grade I and II HemorrhoidsNCT02689856Global score of disease severityRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Hydrocortisone acetate and lidocaine hydrochloride, Placebo control, Hydrocortisone acetate, Lidocaine hydrochloride | Hemorrhoids | 211 | Sep 2015actual | 2016-02-24 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19